Academic Journal
Is there a rationale to supplement hepatotropic factors to dogs with multiple acquired portosystemic shunts secondary to congenital portosystemic shunt attenuation? = Is er wetenschappelijke basis om hepatotrope factoren te supplementeren aan honden met multipele verworven portosystemische shunts secundair aan attenuatie van een congenitale portosystemische shunt?
| العنوان: | Is there a rationale to supplement hepatotropic factors to dogs with multiple acquired portosystemic shunts secondary to congenital portosystemic shunt attenuation? = Is er wetenschappelijke basis om hepatotrope factoren te supplementeren aan honden met multipele verworven portosystemische shunts secundair aan attenuatie van een congenitale portosystemische shunt? |
|---|---|
| المؤلفون: | Van Acker, Lisa, De Rooster, Hilde, Serrano, Gonçalo, Paepe, Dominique, De Spiegelaere, Ward, Devriendt, Nausikaa |
| المصدر: | VLAAMS DIERGENEESKUNDIG TIJDSCHRIFT ; ISSN: 0303-9021 |
| سنة النشر: | 2021 |
| المجموعة: | Ghent University Academic Bibliography |
| مصطلحات موضوعية: | Veterinary Sciences, HEPATOCYTE GROWTH-FACTOR, CHAIN AMINO-ACIDS, CHRONIC HEPATIC-ENCEPHALOPATHY, STIMULATES LIVER-REGENERATION, PORTAL-HYPERTENSION, ALBUMIN SYNTHESIS, RAT HEPATOCYTES, DNA-SYNTHESIS, CANINE MODEL, PROTEIN-DIET |
| الوصف: | Experimental rat models and clinical trials in human patients with liver cirrhosis show evi-dence that supplementation with hepatotropic factors provides therapeutic benefits. This form of support has not yet been described in dogs with multiple acquired portosystemic shunts (MAPSS) despite similarities between both pathological conditions. Especially hepatocyte growth factor (HGF) and branched chain amino acids (BCAA) deserve closer attention. High-quality vegetable rather than animal proteins have been suggested to form an excellent dietary source of BCAA, and leucine seems the best candidate for supplementation given its stimulating effects on liver function in general and on HGF secretion specifically. Research on optimal ways of administra-tion of HGF in dogs with MAPSS secondary to congenital portosystemic shunt attenuation is necessary before clinical trials can be initiated. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| Relation: | https://biblio.ugent.be/publication/8719193; http://hdl.handle.net/1854/LU-8719193; http://dx.doi.org/10.21825/vdt.v90i4.20717; https://biblio.ugent.be/publication/8719193/file/8719944 |
| DOI: | 10.21825/vdt.v90i4.20717 |
| الاتاحة: | https://biblio.ugent.be/publication/8719193 http://hdl.handle.net/1854/LU-8719193 https://doi.org/10.21825/vdt.v90i4.20717 https://biblio.ugent.be/publication/8719193/file/8719944 |
| Rights: | Creative Commons Attribution 4.0 International Public License (CC-BY 4.0) ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.77EDC801 |
| قاعدة البيانات: | BASE |
| DOI: | 10.21825/vdt.v90i4.20717 |
|---|